Literature DB >> 11848726

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Yngve Falck-Ytter1, Hemangi Kale, Kevin D Mullen, Steedman A Sarbah, Lucian Sorescu, Arthur J McCullough.   

Abstract

BACKGROUND: The effect and applicability of interferon-based antiviral therapies in the general population of persons with hepatitis C virus (HCV) infection are unknown.
OBJECTIVE: To determine the applicability and usefulness of anti-viral therapy in a metropolitan clinic population.
DESIGN: Retrospective case series of consecutively referred patients.
SETTING: A teaching county hospital in Cleveland, Ohio. PATIENTS: 327 patients referred to a liver clinic after a positive result for antibody against HCV on enzyme-linked immunosorbent assay (ELISA). MEASUREMENTS: Treatment rates; reasons for nontreatment.
RESULTS: 34 patients had no detectable HCV RNA. Of the remaining 293 patients, 72% were not treated for the following reasons: 37% did not adhere to evaluation procedures, 34% had medical or psychiatric contraindications, 13% had ongoing substance or alcohol abuse, 11% preferred no treatment, and 5% had normal liver enzyme levels. Only 83 patients (28%) were treated; 13% had a sustained viral response.
CONCLUSION: Most patients with HCV infection are not candidates for interferon-based therapies; alternative interventions should be sought for these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11848726     DOI: 10.7326/0003-4819-136-4-200202190-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  98 in total

1.  Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital.

Authors:  Kenneth Kar-Lung Yan; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

2.  The beginning of a new era in understanding hepatitis C virus prevention.

Authors:  Josiah D Rich; Lynn E Taylor
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

3.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

4.  Rate, delay and predictors of hepatitis C treatment in British Columbia.

Authors:  Alan Hoi Lun Yau; Terry Lee; Alnoor Ramji; Hin Hin Ko
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

5.  Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C.

Authors:  D Cheng; E Liu; Y Li; R Liu; L Bai; Y Chen; Y Wang; Y Chu; M Wu; G Cheng; S Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03       Impact factor: 3.267

6.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.

Authors:  Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2010-12-22       Impact factor: 22.682

7.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

8.  Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage.

Authors:  Romain Moirand; Marc Bilodeau; Suzanne Brissette; Julie Bruneau
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

9.  Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.

Authors:  Liliana Gazzuola Rocca; Barbara P Yawn; Peter Wollan; W Ray Kim
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

10.  Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.

Authors:  Kara W Chew; Scott A Allen; Lynn E Taylor; Josiah D Rich; Edward Feller
Journal:  J Clin Gastroenterol       Date:  2009-08       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.